Coya Therapeutics, Inc. (COYA) company profile
Close on Nov 17, 2026Market cap $70.84MP/E –Yield –
About Coya Therapeutics
Pharmaceutical Preparations, SIC 2834
Coya Therapeutics, Inc. is a clinical-stage biotechnology company that develops therapies designed to enhance the function of regulatory T cells, or Tregs. The company explores three therapeutic modalities: Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. Its pipeline addresses neurodegenerative, autoimmune, and metabolic diseases, with primary focus on conditions such as amyotrophic lateral sclerosis, frontotemporal dementia, Alzheimer's disease, and Parkinson's disease. Its lead candidate, COYA 302, is a combination biologic utilizing low-dose interleukin-2 alongside a fusion protein. Another candidate, COYA 303, combines low-dose interleukin-2 with a GLP-1 receptor agonist for inflammatory conditions. Because its product candidates remain in clinical and preclinical development, the company does not have commercial customers.
The company operates through strategic research collaborations, licensing agreements, and partnerships, including research work conducted with Houston Methodist Hospital. Its clinical investigations, such as the multicenter ALSTARS Phase 2 trial, take place in the United States. The provided text does not state the location of the company's corporate headquarters.
Summary of the business section of Coya Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Coya Therapeutics, Inc.
- Headquarters
- Houston, TX
- Address
- 12645 Memorial Dr., Suite F1 #305 77024
- Phone
- (650) 739-3939
- Website
- coyatherapeutics.com
- Employees
- 8, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Weaver and Tidwell, L.L.P., New York, NY
Stock & identifiers
- Ticker
- COYA
- Exchange
- Nasdaq
- IPO date
- Dec 30, 2022
- Shares outstanding
- 23M, Aug 7, 2026
- Public float
- $89.42M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- SEC CIK
- 1835022
- CUSIP
- 22407B108
- ISIN
- US22407B1089
- FIGI
- BBG00Z4HBCB9
- Share class FIGI
- BBG00Z4HBCC8
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Howard Berman | Executive Chairman, Director | 949,338 |
| Arun Swaminathan | Chief Executive Officer, Director | 10,000 |
| David S. Snyder | Chief Financial Officer | 8,800 |
| Fred Grossman | Chief Medical Officer | 2,710 |
| Mark H. Pavao | Director | – |
| Ann Lee | Director | 33,958 |
| Wilbur L. Ross Jr | Director | 165,016 |
| Dieter Weinand | Director | – |
| Dov A. Goldstein Md | Director | 27,557 |
| Anabella Villalobos | Director | 10,000 |
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Option awards | Total | vs. prior year |
|---|---|---|---|---|---|
| Arun Swaminathan Chief Executive Officer, Director | $546.00K | $395.85K | $1.15M | $2.09M | +40% |
| Howard Berman Former Chief Executive Officer, Former Executive Chairman of the Board | $436.80K | $316.68K | $718.22K | $1.47M | -45% |
| David Snyder Chief Financial Officer and Chief Operating Officer | $442.00K | $256.36K | $670.34K | $1.37M | -7% |
| Fred Grossman President, Chief Medical Officer | $498.16K | $288.93K | $670.34K | $1.46M | -23% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Dec 30, 2022
- Offer price
- $5.00
- Securities offered
- 3,050,000
- Gross proceeds
- $15.25M
- Exchange
- Nasdaq
- First trading day
- Dec 29, 2022
- First-day close
- $4.57-8.6%
- Lock-up ends (est.)
- Jun 27, 2023
“Per Share and Accompanying Warrant Total Public offering price $ 5.00 $ 15,250,000 Underwriting discount and commissions ( 1 ) $ 0.35 $ 1,067,500 Proceeds, before expenses, to us ( 2 ) $ 4.65 $ 14,182,500 ( 1 ) Underwriting discounts and commissions do not include the reimbursement of certain expenses of the underwriters we have agreed to”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“We have eight full-time employees, and utilize consultants, contract research organizations and third parties to perform our pre-clinical studies, clinical studies, administrative, and financial functions.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Dec 30, 2022 | IPO | Initial public offering priced (424B4 prospectus) |
| Dec 27, 2022 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?